adenine has been researched along with AIDS-Related Opportunistic Infections in 22 studies
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "to determine the impact of oral tenofovir as part of combination antiretroviral therapy on asymptomatic herpes simplex virus (HSV) shedding." | 7.77 | No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. ( Kaul, R; Raboud, JM; Tan, DH; Walmsley, SL, 2011) |
| "Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment." | 7.72 | Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 7.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| " Using a computer-generated randomisation sequence, we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis (aged ≥18 years with a plasma HIV RNA concentration of >1000 copies per mL) to receive raltegravir 400 mg twice a day, raltegravir 800 mg twice daily, or efavirenz 600 mg once daily plus tenofovir and lamivudine (1:1:1; stratified by country)." | 5.19 | Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. ( Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C, 2014) |
| "Adefovir dipivoxil (ADF) is a novel acyclic nucleoside analogue that has recently been approved for the treatment of chronic hepatitis B virus (HBV)." | 4.82 | Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. ( Danta, M; Dusheiko, G, 2004) |
| "to determine the impact of oral tenofovir as part of combination antiretroviral therapy on asymptomatic herpes simplex virus (HSV) shedding." | 3.77 | No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. ( Kaul, R; Raboud, JM; Tan, DH; Walmsley, SL, 2011) |
| "Combination emtricitabine (FTC) or lamivudine (LAM) with tenofovir disoproxil (TDF) is the recommended first-line regime for treatment in chronic hepatitis B virus (HBV)/HIV co-infection." | 3.77 | Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. ( Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ, 2011) |
| " We report a case of pulmonary aspergilloma in a severely immunocompromised patient with AIDS who stopped taking systemic antifungal treatment in April 1998 and remained well with little progression of invasive aspergillosis up until March 2002 when he died of acute pancreatitis related to a drug interaction of didanosine and tenofovir." | 3.75 | Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary? ( Yoganathan, K, 2009) |
| "Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment." | 3.72 | Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 3.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "Adverse events, including CM immune reconstitution inflammatory syndrome (CM-IRIS), and immunologic and virologic responses were compared over 24 weeks." | 2.78 | Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. ( Bellamy, S; Bisson, GP; Gluckman, S; Molefi, M; Rantleru, T; Ravimohan, S; Steenhoff, A; Tamuhla, N; Tebas, P; Thakur, R; Tsimako, I; Weissman, D, 2013) |
| "Treatment with adefovir dipivoxil for 144 weeks was well tolerated and resulted in significant and sustained reductions in HBV DNA and ALT in HIV/HBV co-infected patients." | 1.33 | Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. ( Benhamou, Y; Biao, L; Brosgart, C; Calvez, V; Chang, CG; Currie, G; Fievet, MH; Marcelin, AG; Poynard, T; Thibault, V; Vig, P; Xiong, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Servato, JP | 1 |
| Loyola, AM | 1 |
| Spini, PH | 1 |
| Spini, TH | 1 |
| de Faria, PR | 1 |
| Cardoso, SV | 1 |
| Allen, ME | 1 |
| Brown, J | 1 |
| Karakas, SE | 1 |
| Pollard, RB | 1 |
| Grinsztejn, B | 1 |
| De Castro, N | 1 |
| Arnold, V | 1 |
| Veloso, VG | 1 |
| Morgado, M | 1 |
| Pilotto, JH | 1 |
| Brites, C | 1 |
| Madruga, JV | 1 |
| Barcellos, NT | 1 |
| Santos, BR | 1 |
| Vorsatz, C | 1 |
| Fagard, C | 1 |
| Santini-Oliveira, M | 1 |
| Patey, O | 1 |
| Delaugerre, C | 1 |
| Chêne, G | 1 |
| Molina, JM | 1 |
| Romero, E | 1 |
| Hernández, JM | 1 |
| Jarilla, F | 1 |
| Yoganathan, K | 1 |
| Lavae-Mokhtari, M | 1 |
| Mohammad-Khani, S | 1 |
| Schmidt, RE | 1 |
| Stoll, M | 1 |
| Elzi, L | 1 |
| Marzolini, C | 1 |
| Furrer, H | 1 |
| Ledergerber, B | 1 |
| Cavassini, M | 1 |
| Hirschel, B | 1 |
| Vernazza, P | 1 |
| Bernasconi, E | 1 |
| Weber, R | 1 |
| Battegay, M | 1 |
| Tan, DH | 1 |
| Kaul, R | 1 |
| Raboud, JM | 1 |
| Walmsley, SL | 1 |
| Ratcliffe, L | 1 |
| Beadsworth, MB | 1 |
| Pennell, A | 1 |
| Phillips, M | 1 |
| Vilar, FJ | 1 |
| Bisson, GP | 1 |
| Molefi, M | 1 |
| Bellamy, S | 1 |
| Thakur, R | 1 |
| Steenhoff, A | 1 |
| Tamuhla, N | 1 |
| Rantleru, T | 1 |
| Tsimako, I | 1 |
| Gluckman, S | 1 |
| Ravimohan, S | 1 |
| Weissman, D | 1 |
| Tebas, P | 1 |
| Daou, S | 1 |
| Ambrosioni, J | 1 |
| Merkler, D | 1 |
| Calmy, A | 1 |
| Danta, M | 1 |
| Dusheiko, G | 1 |
| Schildgen, O | 1 |
| Schewe, CK | 1 |
| Vogel, M | 1 |
| Däumer, M | 1 |
| Kaiser, R | 1 |
| Weitner, L | 1 |
| Matz, B | 1 |
| Rockstroh, JK | 1 |
| Benhamou, Y | 2 |
| Thibault, V | 1 |
| Vig, P | 1 |
| Calvez, V | 1 |
| Marcelin, AG | 1 |
| Fievet, MH | 1 |
| Currie, G | 1 |
| Chang, CG | 1 |
| Biao, L | 1 |
| Xiong, S | 1 |
| Brosgart, C | 1 |
| Poynard, T | 1 |
| Thio, CL | 1 |
| Diller, R | 1 |
| Thompson, K | 1 |
| Cadman, J | 2 |
| Bestman-Smith, J | 1 |
| Boivin, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuber[NCT00822315] | Phase 2 | 155 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis[NCT00976040] | Phase 4 | 28 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for adenine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV | 2013 |
Adefovir dipivoxil: review of a novel acyclic nucleoside analogue.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Hepatitis | 2004 |
[Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Resistance, | 2006 |
3 trials available for adenine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agen | 2014 |
Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Amphotericin B; Anti-HIV Agents; Ant | 2013 |
Hepatitis B and adefovir depivoxil.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Controlled Clinical Trials as Topi | 1997 |
16 other studies available for adenine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Regression of oral Kaposi's sarcoma after combination antiretroviral therapy.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Benzoxazines | 2013 |
Refractory AIDS cholangiopathy: metabolic complications and the role of plasmapheresis.
Topics: Abdominal Pain; Acquired Immunodeficiency Syndrome; Adenine; AIDS-Related Opportunistic Infections; | 2013 |
[Renal tuberculosis and human immunodeficiency virus infection].
Topics: Acute Kidney Injury; Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral | 2009 |
Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary?
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; D | 2009 |
[Telbivudine in the management of HIV/HBV coinfection. Treating hepatitis B without HIV trouble].
Topics: Adenine; AIDS-Related Opportunistic Infections; Algorithms; Anti-HIV Agents; Antiviral Agents; Comor | 2009 |
[Acute renal failure and hypercalcemia in an AIDS patient on tenofovir and low-dose vitamin D therapy with immune reconstitution inflammatory syndrome].
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenine; Adrenal Cortex Hormones; Adult; AI | 2009 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; | 2010 |
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Canada; Female; Herpes Simplex; Herpesvirus 1 | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; D | 2011 |
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directe | 2004 |
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Fem | 2006 |
Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Drug Resistance, Viral | 2006 |
Visual loss secondary to acquired immunodeficiency virus-related progressive multifocal leukoencephalopathy demonstrating clinical improvement with highly active antiretroviral therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Hi | 2007 |
CMV trials struggle to enroll.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Clinical Tri | 1997 |
A rocky road for nucleotide analogs.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials as Topi | 1998 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes | 2002 |